Redefining multiple sclerosis with CAR-T cell therapy.

Area of Science:

• Neuroimmunology
• Cellular Therapy
• Autoimmune Disorders

Background:

• Multiple sclerosis (MS) is a chronic central nervous system autoimmune disease causing progressive neurological impairment.
• Current therapies for MS offer limited remission and do not reverse existing damage.
• Chimeric antigen receptor (CAR)-T cell therapy, successful in oncology, is emerging as a potential treatment for autoimmune diseases like MS.

Purpose of the Study:

• To review recent advancements in applying CAR-T cell therapy to multiple sclerosis.
• To discuss challenges and future directions for CAR-T cell therapy in neuroimmunology.
• To explore the potential of CAR-T cells for achieving long-lasting disease control in MS.

Main Methods:

• Review of preclinical studies and early-phase clinical trials of CAR-T cell therapy in MS.
• Analysis of lessons learned from CAR-T cell applications in oncology and other autoimmune diseases.
• Discussion of strategies for optimizing antigen targets and minimizing toxicities.

Main Results:

• CAR-T cell therapy targeting CD19+ B cells has demonstrated encouraging efficacy in preclinical and early clinical studies for autoimmune conditions, including MS.
• The approach holds potential for selective elimination of autoreactive immune cells, offering a pathway to immune system reset.
• Significant challenges persist, including toxicity management, sustained therapeutic benefit, and scalable clinical implementation.

Conclusions:

• CAR-T cell therapy represents a promising frontier for managing multiple sclerosis, potentially offering durable remission and reversal of pathology.
• Overcoming challenges in antigen selection, safety, and manufacturing is crucial for translating CAR-T cell therapy into standard clinical practice for MS.
• Further research and clinical trials are essential to establish CAR-T cells as a transformative treatment in neuroimmunology.